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Abstract
Background: Beta blockers are recommended by the American College of
Cardiology/American Heart Association Guidelines for high and intermediate-risk
cardiac patients undergoing non-cardiac surgery. Beta blockers are a class of drugs that
moderate the effects of increased catecholamine levels on the heart by selectively
blocking beta receptors in the heart and blood vessels, resulting in a lower heart rate and
blood pressure. Beta blocker use perioperatively has been shown to reduce the risk of
ischemia and infarction.
Purpose: The purpose of this project is to address beta blocker use in a group of
anesthesia providers who routinely attend to high-risk and intermediate-risk cardiac
patients undergoing non-cardiac surgery in a medium-sized private hospital in suburban
South Florida. There are barriers to the implementation of the published guidelines for
beta blocker administration, including lack of awareness of the best current practice and a
lack of a formal beta blocker protocol at the institutional level.
Methods: A simple and inexpensive beta blocker protocol was implemented and
evaluated by various means. Beta blocker administration practices were examined and
documented prior to and after protocol implementation. Beta blocker usage was
examined prior to and after protocol implementation
Findings/Implications: It was hypothesized that increased anesthesia provider
awareness would lead to increased administration of perioperative beta blockers to highrisk and intermediate-risk cardiac patients undergoing non-cardiac procedures. Although
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there was a knowledge increase related to the new beta blocker protocol, no change in
practice was observed.

Chapter 1: Introduction
Problem Identification
According to published estimates, 27 million non-cardiac surgeries are performed
in the United States annually; four to six percent of patients with cardiac disease or
cardiac risk factors undergoing non-cardiac surgery will have a myocardial infarction
(MI), up to 1% will have a stroke, and 2-3% will die of cardiac and non-cardiac causes
(White et al., 2010). The leading cause of postoperative morbidity and mortality is
perioperative MI (Savio et al., 2011). There is a mortality rate of 15-25% in patients
having an MI after non-cardiac surgery and a mortality rate of 65% in patients having a
cardiac arrest after non-cardiac surgery (Devereaux et al., 2005). Perioperative
complications can prolong hospital stays significantly, add to overall healthcare costs,
and consume healthcare resources.
Beta blocker use perioperatively has been shown to reduce the risk of ischemia
and infarction, and is recommended by the American Heart Association and the
American College of Cardiology (Beckman et al., 2006) for patients already on beta
blockers and high-risk patients having non-cardiac surgery. The recommendations are
not as clear for intermediate and low-risk patients (White et al., 2010). Appropriate
perioperative beta blockade in high-risk patients has been a national standard of care
since 1996, although guidelines for implementation have been updated several times and
continue to evolve (Wallace, Au, & Cason, 2010). Not all institutions and anesthesia
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providers follow this standard of care or the ACC/AHA guidelines consistently
(Lindenauer et al., 2005).

Abbreviated Literature Review
Numerous trials have looked at the benefits and risks of beta blocker therapy in
various patient populations. A literature search was conducted using the search terms
perioperative beta blockers and perioperative beta blocker protocols. PUBMED and
CINAHL were queried. PUBMED returned 78 articles using the following limits:
humans; clinical trials; meta-analyses; practice guidelines; English; MEDLINE; Adults
19+; 1995-2011. CINAHL returned 49 full text articles dated between 1995 and 2011.
Four random controlled trials (RCTs) evaluated the perioperative use of beta
blockers in non-cardiac surgery; first, the Perioperative Ischemia Evaluation (POISE)
looked at 8351 patients with a 30-day follow up; second, the Beta Blocker in Spinal
Anesthesia (BBSA) looked at 219 patients with a 1-year follow-up; third, in the Atenolol
Study, Mangano, Layug, Wallace, and Tateo (1996) looked at 200 patients with a 2-year
follow-up; fourth, the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography (DECREASE), looked at 112 patients with a 30-day follow-up. The
Atenolol and DECREASE studies were influential in increasing perioperative beta
blocker administration and this led to clinical practice guidelines, institutional
benchmarking, and performance measures. Not everyone was convinced that aggressive
beta blockade was safe and effective; the Atenolol and DECREASE trials were both
criticized for their small sample size, lack of placebo control, and the chosen method of
statistical analysis (London, 2008). White, et al. (2010) critiqued these four RCTs and
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concluded that the use of beta blockers reduces the MI rate but increases the frequency of
stroke, severe hypotension, and severe bradycardia. Wallace et al. (2010) showed a
significant association between perioperative beta blockade and postoperative survival in
patients with existing indications for beta blockade.
Historical Development of Guidelines
The 1996 Atenolol Study provided evidence that perioperative beta blockers
reduced mortality. In 1998, Wallace et al. developed a protocol based on this evidence
and called it the Perioperative Cardiac Risk Reduction Therapy (PCRRT); until its
introduction, only patients in RCTs received perioperative beta blockers by study specific
protocols. The PCRRT protocol is simple and easy to follow and has been adopted by a
number of hospitals and hospital systems (Wallace et al., 2010).
In 2001, the Agency for Healthcare Research and Quality (AHRQ) recommended
the use of beta blockers to reduce perioperative cardiac events and mortality in high-risk
patients undergoing non-cardiac surgery. However, controversies remained in the
literature regarding the use of beta blockers in patients of low or moderate risk having
non-cardiac surgery (VanDenKerhof, Milne, & Parlow, 2003).
The American College of Cardiology and the American Heart Association Task
Force on Practice Guidelines issued a 2006 focused update on perioperative beta blocker
therapy in response to this therapy becoming a quality measure for the Physicians
Consortium for Performance Improvement and the Surgical Care Improvement Project
(Beckman et al., 2006). The recommendations produced by the Task Force were
intended for use in these national quality initiatives and contained three levels of
evidence (A, B, and C), and three classes of recommendations (Class I; Class II, a and b;
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and, Class III). The focused update recommendations were integrated into the revised
ACC/AHA guidelines on perioperative cardiovascular evaluation for non-cardiac surgery
in 2009. The 2009 ACC/AHA consensus guidelines state that there is a Class I
recommendation to continue beta blockers in patients who are currently taking them and
a Class IIa recommendation to start titrated beta blockers in patients with coronary artery
disease or in intermediate to high-risk patients. There is also a Class IIb recommendation
for beta blockers in intermediate to low-risk patients, although the usefulness is uncertain
(Eldrup-Jorgensen, 2011).
Clinical Practice
Anesthesia providers usually practice autonomously and are relatively free to
implement evidence-based practices and clinical guidelines in the operating room (OR),
limited only by the drugs and equipment available. Limiting factors include available
choice of beta blockers, lack of consensus in the literature regarding the best choice of
beta blocker, and fear of possible iatrogenic complications (VanDenKerhof et al., 2003;
Baxter & Kanji, 2007).
The integration of a simple and inexpensive beta blocker protocol into routine
clinical practice can lead to improved outcomes in select cardiac patients undergoing
non-cardiac surgery (Armanious, Wong, Etchells, Higgins, & Chung, 2003; Baxter &
Kanji, 2007; Wallace et al., 2010). Successful protocol implementation requires clinician
acceptance, participation, and evaluation (Baxter & Kanji, 2007). Numerous protocols
have been published in the anesthesia literature and implemented with varying degrees of
success. One such protocol implemented in the Ottawa Hospital, Ottawa, Canada,
demonstrated that the standardization of a perioperative protocol to identify at-risk
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patients coupled with heightened anesthesia provider awareness led to an increase in beta
blocker use and a reduction in adverse cardiac events (Baxter & Kanji, 2007).
The Problem
Evidence exists to support the use of beta blockers in high-risk and intermediaterisk cardiac patients undergoing certain non-cardiac procedures. The purpose of this
project was to address the use of beta blockers in a group of anesthesia providers, both
certified registered nurse anesthetists (CRNAs) and medical doctor anesthesiologists
(MDAs) who routinely attend to high-risk and intermediate-risk cardiac patients
undergoing non-cardiac surgery in a medium-sized, private suburban hospital in the
Southeastern United States. The study was implemented and evaluated. Beta blocker
administration practices were examined and documented prior to and after protocol
implementation. It was hypothesized that increased anesthesia provider awareness of the
ACC/AHA guidelines for beta blocker administration would lead to increased
administration of beta blockers to high-risk and intermediate-risk cardiac patients
undergoing non-cardiac procedures. The PICO question used to identify the evidence for
the project was “In anesthesia providers caring for cardiac patients undergoing noncardiac surgery how does an increase in awareness of ACC/AHA guidelines for
perioperative beta blocker administration influence compliance and decrease major
perioperative complications?”

Definitions
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Anesthesia Provider
A certified registered nurse anesthetist (CRNA) is an advanced practice registered
nurse (APRN) who has acquired graduate-level education and board certification in
anesthesia. A medical doctor anesthesiologist (MDA) is a medical doctor who has
successfully completed an accredited residency program in anesthesia. No board
certification is necessary to practice.
Risk
The Revised Cardiac Risk Index (RCRI) is a clinical prediction rule for use
during preoperative care for prediction major cardiac complications of non-cardiac
surgery originally published in 1977; six equally weighted cardiovascular risk factors
(high-risk surgery, history of ischemic heart disease, history of congestive heart failure,
history of cerebrovascular disease, preoperative treatment with insulin, preoperative
serum creatinine level >2.0 mg/dl) are scored one point each. Low-risk is one point or
less, moderate-risk is two points, high-risk is three or more points.
Protocol
Protocol is a document that describes in detail the plan for conducting a clinical
study. The study protocol explains the purpose and function of the study as well as how
to carry it out. It describes the objectives, design, methodology, statistical considerations,
and organization of the clinical trial.
Clinical Practice Guidelines
Clinical practice guidelines are systematically developed statements to assist
practitioner and patient decisions about appropriate health care for specific clinical
circumstances (Institute of Medicine, 1990).
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Summary
In summary, Chapter One introduced the challenges/problems with beta blocker
use, the potential benefits of using beta blockers, an abbreviated literature review, and a
brief description of the proposed project. Research questions used to search the literature
and definitions were also provided.
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Chapter Two: Review of the Literature
In this chapter, a more thorough review of the literature is included. The role of
beta blockers in preventing perioperative cardiac events is examined, methods of risk
identification and reduction are identified, literature supporting the use of perioperative
beta blockers is evaluated, and a critical appraisal of the literature is presented. A
literature search was conducted using Medline, CINAHL, and PUBMED for high level
evidence using the following key terms: perioperative beta blockers and perioperative
beta blocker protocols. Articles dating back to 1995 that had the key terms were
reviewed.
Role of Beta Blockers
Beta blockers have been used clinically since the 1960s to treat hypertension,
heart failure, and coronary artery disease. They exert their beneficial anti-arrhythmic,
anti-inflammatory, and anti-renin-angiotensin effects by blocking beta 1 and 2 receptors
found throughout the body. The major direct effects are heart rate reduction, which
increases diastolic perfusion time; and reduced myocardial contractility, which reduces
myocardial oxygen demand. Beta blockers decrease sympathetic tone, which indirectly
reduces inflammation and shear stress leading to stabilization of coronary plaques. The
physiological rationale for perioperative beta blockade is to reduce the stress state
brought on by surgery with its associated fasting, anesthesia, intubation, extubation, pain,
hypothermia, and bleeding (Devereaux et al., 2005). This stress state involves increased
cortisol and catecholamine levels leading to increases in heart rate, blood pressure,
coronary artery shear stress, insulin deficiency, and free fatty acids. These factors can all
lead to increased oxygen demand and perioperative myocardial ischemia, which is
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strongly associated with preioperative myocardial infarction (Devereaux et al., 2005).
Beta blockers can attenuate both kinds of perioperative MIs; those caused by an
asymptomatic coronary plaque rupturing in patients with multiple risk factors for MI but
no critical stenosis, and those with a fixed coronary stenosis leading to a predisposition to
mismatch myocardial oxygen supply and demand. Studies have shown that a significant
proportion of fatal perioperative MIs are due to an increase in oxygen demand in the
setting of fixed coronary stenosis (decreased supply) (Landesberg, 2003).
Risk Identification
The key to successful prevention of perioperative cardiac events in non-cardiac
surgery lies with identifying patients at risk for these events and optimizing them before
surgery. Patients with active cardiac conditions need to be identified, evaluated, and
treated before surgery. Simple clinical markers can identify patients at increased risk for
perioperative cardiac events. The Revised Cardiac Risk Index is a common preoperative
risk stratification strategy that has been validated in prospective studies and is based on
the Lee Index (Lee et al., 1999). Six equally weighted cardiovascular risk factors (highrisk surgery, history of ischemic heart disease, history of congestive heart failure, history
of cerebrovascular disease, preoperative treatment with insulin, preoperative serum
creatinine level >2.0 mg/dl) are scored one point each. Perioperative cardiac
complications with no risk factors are 0.4%, one risk factor 0.9%, two risk factors 7%,
and three or more risk factors 11%. The ACC/AHA algorithm for preoperative risk
assessment can also be used to stratify cardiac patients undergoing non-cardiac surgery.
It is limited in its validity as it was not derived from a prospective study and includes
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judgments from committee members (expert opinions) (Devereaux et al., 2005). Once
perioperative risk has been quantified, risk mitigation can be considered.
Prophylactic perioperative use of beta blockers in high-risk and intermediate-risk
cardiac patients undergoing non-cardiac surgery may be protective and reduce the risk of
perioperative cardiovascular complications. The first RCT addressing the issue of
perioperative beta blockers was conducted by Mangano et al. in 1996 (Mangano et al.,
1996). The authors concluded that the perioperative administration of atenolol decreased
perioperative ischemia and caused an increased rate of event-free survival at six months
in 200 high-risk cardiac patients undergoing non-cardiac surgery. As part of the
Multicenter Study of Perioperative Ischemia Research Group, Dr. Wallace at UCSF-VA
Medical Center developed a perioperative cardiac risk reduction therapy (PCRRT) using
beta blockers and clonidine for those patients in whom beta blockers are contraindicated
(BBAC). Perioperative myocardial ischemia is a risk factor that can actually be
modified, unlike fixed risk factors such as age, hypertension, peripheral vascular disease,
diabetes, coronary artery disease, and hyperlipidemia. Prophylactic beta blockers are one
medical therapy that can modify and reduce the risk of perioperative cardiac morbidity
and mortality by up to 90% (Wallace, 1998).
Literature Review
In appraising the literature, multiple levels of evidence were reviewed. Articles
on perioperative use of beta blockers ranging from case studies to systematic reviews
were all appraised. This paper reviews multiple levels of evidence; two randomized
studies, and two combined meta-analysis and systematic reviews. Two large,
longitudinal cohort studies are also examined, as well as two expert reviews.
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Randomized Controlled Studies
The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress
Echocardiography (DECREASE) study by Poldermans et al. (1999), examined 112 highrisk patients undergoing major vascular surgery in a randomized, multi-center study.
High-risk patients were identified by clinical risk factors and positive results on
dobutamine stress echocardiography. Patients were stratified to receive bisoprolol, a beta
blocker (59 patients), or placebo (53 patients); the group randomized to bisoprolol had
significant reductions in perioperative cardiac death and nonfatal MI. The overall rate of
the combined endpoint of nonfatal myocardial infarction and death from cardiac causes
was 34% (95% CI, 21 to 48%) in the placebo group, compared to 3.4% (95% CI, 0 to
8%) in the bisoprolol group. The estimated relative risk of death in the bisoprolol group
compared to the placebo group was calculated to be 0.09 (95% CI, 0.02 to 0.37)
(P<0.001). Statistical analysis methods were presented and were appropriate for the data.
The high rate of serious perioperative events in the placebo group was considered
consistent with other studies on similar high-risk patients. The authors concluded that
bisoprolol reduced the perioperative incidence of death from cardiac causes and nonfatal
MI in high-risk patients undergoing major vascular surgery. The limitations of this study
included its lack of blinding, although no major differences were found by the authors in
the major aspects of perioperative treatment across the eight institutions involved in the
study; this lack of blinding may have contributed to reporting errors and bias on the part
of the investigators. The importance of this study was the decrease in death and other
serious perioperative complication in high-risk patients.
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The Perioperative Ischemic Evaluation (POISE) trial by Devereaux et al. (2006)
was designed to investigate the effects of perioperative beta blocker use. It was a large,
random controlled trial that instituted a single large dose of oral, extended release
metoprolol (a beta blocker) in 8,351 beta blocker naïve, at-risk patients in 190 hospitals
in 23 countries (4,144 in the metoprolol group and 4,177 in the placebo group). Study
treatment was started 2-4 hours before surgery and continued for 30 days. The
prespecified primary outcome was a composite of cardiovascular death, nonfatal MI, and
nonfatal cardiac arrest at 30 days after randomization. Analyses were by intention to
treat. Statistical analysis methods were appropriate for the data and all 8,351 patients
were included.
The authors found statistically significant reductions in the primary outcomes of
cardiac death, nonfatal MI, and cardiac arrest (hazard ratio 0.84, 95% CI 0.70-0.99;
P=0.0399); this beneficial effect resulted from fewer MIs in the metoprolol group. The
beneficial effect was counterbalanced by an increase in stroke (hazard ratio 2.17, 95% CI
1.26-3.74; P=0.0053) and non-cardiac death (hazard ratio 1.33, 95% CI 1.03-1.74;
P=0.0317) in the beta blocker group versus the controls. The authors concluded that the
results of this trial provide evidence that perioperative beta blockers prevent nonfatal MIs
but increase the risk of nonfatal stroke, and that the variable beneficial effects of beta
blockers were correlated with risk assessment, as the incidence of perioperative
complications was contingent upon the number of risk factors present (high-risk surgery,
ischemic heart disease, congestive heart failure, cerebrovascular disease, insulindependent diabetes, and renal failure). Limitations to the study included the possible
inappropriate (both the dosage and the timing of administration) acute administration of
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high-dose beta blocker therapy to beta blocker naïve patients. This study points out the
importance of risk stratification and the beneficial effects of beta blockers in at-risk
patients undergoing non-cardiac surgery.
Systematic Reviews and Meta-Analyses
Devereaux et al. (2005) published a systematic review to determine the
effectiveness of perioperative beta blocker treatment in patients having non-cardiac
surgery. Using seven search strategies, they identified twenty-two trials that randomized
a total of 2,437 patients. Eligibility criteria included perioperative outcomes within thirty
days of surgery, total mortality, cardiovascular mortality, nonfatal MI, nonfatal stroke,
nonfatal cardiac arrest, hypotension needing treatment, bradycardia needing treatment,
and bronchospasm. Two researchers independently evaluated study eligibility (k=0.96)
and abstracted data (k=0.69-1.0). Outcomes were defined as above plus the composite
outcome of major perioperative cardiovascular events (cardiovascular death, nonfatal MI,
nonfatal cardiac arrest). Perioperative beta blockade did not show any statistically
significant beneficial effects on any of the individual outcomes, but did show a
significant beneficial relative risk of 0.44 (95% CI 0.20-0.97) for the composite outcome
of cardiovascular mortality, nonfatal MI, and nonfatal cardiac arrest.
The stated strengths of the review were the multiple search strategies used to
identify RCTs, verification of the data with all trialists, and evaluation of the reliability
and conclusiveness of the available evidence using formal interim monitoring boundaries.
The stated weaknesses of the review were the focus on short-term (30 day) outcomes, as
it is possible that perioperative beta blockers affect long term outcomes, and the
heterogeneity of the included studies, which weakens the reliability of the findings. The
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authors concluded that their review provides encouraging evidence that perioperative beta
blockers may reduce the risk of major cardiovascular events during the perioperative
period. However, the evidence seems too unreliable to draw definitive conclusions. This
is an important review as it supports the use of beta blockers in high-risk patients
undergoing non-cardiac surgery.
A more recent systematic review and meta-analysis was conducted by Savio et al.
in 2011. The authors searched electronic databases for RCTs of the perioperative use of
esmolol (a short-acting intravenous beta blocker) in non-cardiac surgery. Statistical
heterogeneity was assessed primarily by meta-regression. Their search identified 67
trials of 3,766 patients undergoing non-cardiac surgery. Data was extracted from the
selected trials by two reviewers and included patient characteristics, study quality, drug
dosages, methods of administration, changes in vital signs, and incidence of unplanned
hypotension, bradycardia, myocardial ischemia, MI, and death. The quality of the studies
was limited by small sample size and poorly defined allocation concealment. In the
seven trials reporting the effect of esmolol on the magnitude and frequency of myocardial
ischemia, it was found to decrease the frequency of myocardial ischemia in comparison
with placebo (OR 0.17, 95% CI 0.02-0.45 p<0.001). The effects of esmolol on the
incidence of perioperative MI or stroke were not assessed because these events were too
infrequent in the retrieved studies. In the 67 studies, there were 6 documented MIs and
no reported strokes.
The stated strengths of the review were: scrutinizing the text of each study for all
adverse effects; including all adverse effects in the primary analysis; contacting all
selected authors for missing information, unpublished data, or clarification of the results.
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The effect of study quality on the outcome was compared using trial size, allocation
concealment, and blinded outcome adjudication. The stated weaknesses of the review
were: the quality of the included studies was mixed; the sample sizes were generally
small (the median size was 40 patients); 4 studies had no blinding protocol; allocation
concealment was only reported in 5 studies; 10 studies did not conduct an intention-totreat analysis. The authors concluded that esmolol has the potential to be both a safe and
effective drug by providing protection against myocardial ischemia in patients
undergoing non-cardiac surgery. This is an important conclusion as esmolol is readily
available perioperatively, has a rapid onset and a short half-life, and can be titrated to the
desired effect. The authors also recommended further studies of esmolol use in high-risk
patients to establish a perioperative safety and efficacy profile for esmolol.
Cohort Studies
Lindenauer et al. (2005) conducted a retrospective cohort study of 782,969
patients, 18 years or older, who underwent major non-cardiac surgery in 329 hospitals
throughout the United States between 2000 and 2001. The data was extracted from
Premier’s Perspective, a database developed for measuring the quality and use of
healthcare. The authors used propensity-score matching to adjust for differences between
those who received beta blockers and those who did not, and compared in-hospital
mortality using multivariable logistic modeling. They concluded that the relationship
between perioperative beta blocker treatment and the risk of death varied directly with
cardiac risk. Among the 580,665 patients with a RCRI score of 0 or 1, treatment was
associated with no benefit and possible harm. Among the patients with a RCRI score of
2, 3, or 4 or more, the adjusted odds ratio for death in the hospital for each was 0.88 (95%
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CI, 0.80 to 0.98), 0.71(95% CI, 0.63 to 0.80), and 0.58(95% CI, 0.50 to 0.67),
respectively. This study showed that beta blockers were clearly beneficial in moderate
and high-risk patients (two or more risk factors) undergoing major non-cardiac surgery,
and that there was no benefit and possible harm in low-risk patients (less than two risk
factors). The authors concluded that ongoing national efforts to increase patient safety by
increasing the perioperative use of beta blockers appear warranted as the use of beta
blockers was associated with a reduced risk of death in the hospital among at-risk patients
undergoing major non-cardiac surgery.
Wallace et al. (2010) conducted an epidemiological analysis of 38,799 operations
performed at the San Francisco VA Medical Center between 1996 and 2008. Four
patterns of beta blocker use were identified: none, addition, withdrawal, and continuous.
Logistic regression, survival analysis, and propensity analysis were performed. The
perioperative addition of a beta blocker to the medical management of patients with 2 or
more risk factors was associated with improved 30 day (OR 0.52, 95% CI 0.33-0.83,
p=0.0006) and 1 year survival (OR 0.64, 95% CI 0.51-0.79, p=0.0001), as was the
continuous use of beta blockers (30 day OR 0.68, 95% CI 0.47-0.98, p=0.04) (1 year OR
0.82,95% CI 0.67-1.0, p=0.05) in patients already on them, during the perioperative
period compared to patients receiving none. Withdrawal of beta blockers during the
perioperative period resulted in increased risk for 30 day (OR 3.93, 95% CI 2.57-6.01,
p=0.0001) and 1 year (OR 1.96, 95% CI 1.49-2.58, p=0.0001) mortality. The authors
found that undertreatment with beta blockers is still common, and that prospective risk
assessment and treatment with beta blockers could potentially reduce perioperative
mortality further still. The authors also found that the association between the risk of
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death and perioperative beta blocker treatment varied with cardiac risk; patients without
identifiable cardiac risk had no benefit and possible harm from perioperative beta
blockers.
Expert Reviews
An expert review by Flu et al. (2009) provided an extended overview of leading
observational studies, meta-analyses, RCTs, and guidelines assessing perioperative beta
blocker therapy. The authors summarized the studies, guidelines, and meta-analyses to
allow readers to place their strengths and weaknesses into perspective. They identified
the key issues: patients undergoing major non-cardiac surgery are at high risk for
cardiovascular morbidity and mortality; the majority of cardiac events in patients
undergoing major vascular surgery are asymptomatic; the high frequency of perioperative
cardiac complications reflects the high incidence of underlying coronary artery disease.
Treatment recommendations based on the current literature and the experience of the
authors were provided. They proposed that all intermediate and high-risk patients
undergoing high-risk vascular procedures be treated with low-dose beta blockers, ideally
started 30 days before surgery. The goal of the beta blocker therapy should be to achieve
a heart rate of between 65-70 beats per minute. Withdrawal of beta blocker therapy
shortly before surgery or in the immediate postoperative period was strongly discouraged,
as it may lead to adverse myocardial effects. They concluded that adequate heart rate
control by beta blockers exerts a beneficial effect towards postoperative morbidity and
mortality.
A second expert review was published in 2010 by White et al. to describe the
benefits and risks associated with the use of beta blockers in non-cardiac surgery. It was
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aimed at pharmacists to provide brief advice on how to handle specific drug therapy
problems as part of a clinical consultation series. The stated purpose of the article was to
critique key RCTs and meta-analyses evaluating the perioperative use of beta blockers in
non-cardiac surgery. According to the authors, the choice of articles to critique was
based on a systematic review of the literature and included the POISE and the
DECREASE trials described above. The authors concluded that the use of perioperative
beta blockers in non-cardiac surgery can protect against postoperative MI but may
increase the risk of hypotension, bradycardia, and stroke.
Conclusion
Based on the findings of this literature review, the existing consensus is that beta
blockers should be used perioperatively in high and intermediate-risk cardiac patients
undergoing major non-cardiac surgery.
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Chapter Three: Methodology
The purpose of this evidenced-based project was to evaluate the effectiveness of a short
training program for anesthesia providers to increase their use of beta blockers in high
and intermediate-risk cardiac patients undergoing non-cardiac surgery. The project
design is an interventional one-group pre-test, post-test study. The research questions
were as follows:
1. Was there a change in the percentage of anesthesia providers using beta
blockers before and after the PowerPoint intervention?
2. Was there a change in the perception of anesthesia providers regarding the use
of perioperative beta blockers before and after the PowerPoint intervention?
3. Was there a change in the amount of beta blockers used perioperatively before
and after the PowerPoint intervention?

Sample
A convenience sample of anesthesiologists and certified registered nurse
anesthetists at a medium-sized hospital in suburban south Florida were asked to
participate.
Methods
This interventional, one-group pre-test post-test study design consisted of the
following:
1. The primary investigator conducted a retrospective review of the pharmacy
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records to quantify beta blocker usage during the perioperative period. The
time frame for the review was the 3-month period immediately preceding the
pre-test and planned intervention.
2. All Health Insurance Portability and Accountability Act information was
honored. Data on individual patients was used in aggregate form only.
3. All eligible anesthesia providers completed a pre-test, a post-test, and viewed
a PowerPoint presentation on patient selection for beta blocker administration.
4. Pharmacy records for the 3-month period of time following the intervention
were assessed for the quantity of beta blockers administered to patients in the
perioperative period. The outcome of interest was the increase in use of beta
blockers in perioperative patients after the intervention. This outcome was
evaluated 3 months after the participants viewed the PowerPoint presentation.
Setting
The study took place at a large suburban hospital in South Florida. This hospital
is a private, 450 bed full-service facility that has been providing a range of healthcare
services to residents of Fort Lauderdale, Florida for over 50 years. It is fully accredited
by the Joint Commission and specializes in comprehensive adult medical care, orthopedic
surgery, bariatric surgery, a complete range of cardiovascular services, and maternal and
newborn care.
Data Collection and Evaluation
Once Institutional Review Board (IRB) approvals and written consents were
obtained, participants were asked to complete an anonymous one-page pre-intervention
questionnaire on their knowledge and practice regarding perioperative use of beta
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blockers. When all questionnaires were completed, a 25-slide PowerPoint was emailed to
all eligible anesthesia providers outlining the use of beta blockers in cardiac patients
undergoing non-cardiac surgery. This evidence-based intervention was designed to give
the anesthesia providers the best information about perioperative beta blocker use. The
intended outcome of this intervention was to increase the use of beta blockers at this
facility thereby improving patient outcomes. This project took place over 3 consecutive
months. Final data collection was completion of the same anonymous questionnaire 3
months following the pre-intervention questionnaire. The data collected on beta blocker
usage during the 3-month study period was compared to beta blocker usage for the 3
months immediately preceding the pre-intervention questionnaire.
Feasibility and Resources
The resources needed to ensure project completion include the facility keeping
beta blockers stocked in the operating rooms, the pre-anesthesia area, and the postanesthesia care unit. Medications were charged to the patient so that there were usually
no budgetary considerations. As beta blockers cost much less that the cost of treating a
perioperative MI, this financial plan justified the need, feasibility, and sustainability of
the proposed project.
Institutional Review Board
Institutional Review Board (IRB) approval was obtained from both the University
of North Florida (UNF), and the participating clinical site through Western Institutional
Review Board (WIRB). Once both IRBs formally approved, data collection began. All
data was collected anonymously and handled in an aggregate manner. There was no need
to connect participant responses from pre-test to post-test, so there was no master list or
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any identifying information. Prior to starting the project, signed consent was obtained,
scanned into UNF’s secure server, then shredded and discarded. There was no link
between consent and participant responses. The raw data will be kept for three years.
Data Analysis
Raw data was entered into Vovici at UNF, and checked for errors. Analysis was
performed using SPSS statistical software (version 16.0, 2005, Chicago, IL) with
statistical significance determined at p<0.05. Descriptive statistics were also used. The
Wilcoxon Signed-Rank Test was performed in order to examine between group
differences in the use of beta blockers from pre-test to post-test. This evidence-based
practice project looked to see if there was a change in overall anesthesia practice with
regard to beta blocker administration. In the event that participants dropped from the
study, it did not impact the project since only overall change was measured. This change
in practice was quantified by comparing beta blocker usage for the 3 months preceding
the intervention with usage for the 3 months after the intervention by examination of
pharmacy records.
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Chapter Four: Results
This chapter describes the study population using mean scores and frequency of
the variables. Analyses were executed using SPSS statistical software (version 16.0,
2007, Chicago, IL) with statistical significance determined at p ≤0.05. Data were
analyzed using descriptive statistics and the Wilcoxon Signed-Rank Test to determine
group differences between pre-test to post-test assessments.
A total of 19 anesthesia providers participated in this evidence-based practice
project; 16 were male (78.9%) and 3 were female (21.1%). No provider was under age
30, three (15.8%) were 30-39, seven (36.8%) were 40-49, six (31.6%) were 50-59, and
three (15.8%) were over 60. Three providers had been in practice for 5 years or less
(15.8%), two providers had been in practice 5-10 years (10.5%), two providers had been
in practice 10-15 years (10.5%), seven providers had been in practice 15-20 years
(36.8%), and five providers had been in practice over 20 years (26.3%).
Pre-Intervention Results
At the beginning of the study period all of the anesthesia providers were aware of
studies in the literature related to prophylactic perioperative beta blocker use in cardiac
surgical patients undergoing non-cardiac surgery who are at risk for cardiac
complications (100%). Only five providers (26.3%) were aware of the anesthesia
department protocol for prophylactic beta blocker blockade in patients scheduled for noncardiac surgery who are at risk for cardiac complications. Eight providers (42.1%) were
not aware, and six providers (31.6%) were not sure if there was a department protocol. A
risk assessment tool was used by three providers (15.8%) all the time, six providers
(31.6%) frequently, six providers (31.6%) occasionally, and four providers (21.1%) never
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used a risk assessment tool. Opinions on the prophylactic administration of beta blockers
to patients with known coronary artery disease and patients with two or more risk factors
for coronary artery disease differed: fourteen providers (73.7%) strongly agreed, and five
providers (26.3%) mildly agreed that prophylactic beta blockers have an effect on
postoperative outcomes; eleven providers (57.9%) strongly agreed, five providers
(26.3%) mildly agreed, and three providers (15.8%) neither agreed nor disagreed that
prophylactic beta blockers have an effect on postoperative outcomes in patients that have
two or more risk factors for coronary artery disease.
Post-Intervention Results
Seventeen of the original nineteen participants filled out the post-test
questionnaire. Two anesthesia providers resigned and relocated elsewhere during the
study period. At the end of the study period, five providers (29.4%) were aware of the
department protocol for perioperative beta blocker administration, eight providers
(47.1%) were not aware, and four providers (23.5%) were not sure. A risk assessment
tool was used by three providers (17.6%) all of the time, six providers (35.3%)
frequently, four providers (23.5%) occasionally, and four providers (23.5%) never.
Opinions on the prophylactic administration of beta blockers to patients with known
coronary artery disease and patients with two or more risk factors for coronary artery
disease differed: fourteen providers (82.4%) strongly agreed, and three providers (17.6%)
mildly agreed that prophylactic beta blockers have an effect on postoperative outcomes;
twelve providers (70.6%) strongly agreed, three providers (17.6%) mildly agreed, and
two providers (11.8%) neither agreed nor disagreed that prophylactic beta blockers have
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an effect on postoperative outcomes in patients that have two or more risk factors for
coronary artery disease.
Beta Blocker Inventory
A total of 211 doses of beta blockers (esmolol and metoprolol) were dispensed in
the perioperative setting (not including the cardiac operating rooms) between March 21,
2012 and June 21, 2012, comparable to 220 doses dispensed during the study period of
June 22, 2012 through September 21, 2012. The perioperative setting is comprised of the
OR Holding area, where all surgical patients are prepared for surgery; the 16 non-cardiac
operating rooms in the Main OR; and the PACU (post anesthesia care unit), where all
surgical patients, except post-open heart patients, are recovered. The increase of nine
doses of beta blockers is not statistically significant (p>0.05), nor is it clinically
significant.
Conclusion
The results indicate that all of the anesthesia providers were aware of studies in the
literature related to prophylactic perioperative beta blocker use in cardiac surgical
patients undergoing non-cardiac surgery who are at risk for cardiac complications. This
knowledge and the 25-slide PowerPoint intervention were unsuccessful in changing
provider practice as there was no increase in the number of beta blockers used or in the
use of a risk assessment tool. There was also no increase in provider awareness about the
beta blocker protocol that was implemented.
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% Aware of Protocol
50.00%
40.00%
30.00%
20.00%
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Figure 4.1. Protocol Awareness.
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220

Figure 4.2. Beta Blockers Dispensed
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Chapter Five: Discussion
This chapter provides a discussion of the anesthesia providers’ use of
perioperative beta blockers, interventions to promote beta blocker usage, and lessons
learned in the process. Implications for evidence-based practice and future research are
also presented.
Discussion of Use of Beta Blockers
This evidence-based project did not produce the results that this investigator
expected; there was no change in the percentage of anesthesia providers using beta
blockers before and after the PowerPoint intervention. This conclusion was supported by
the absence of any increase in beta blockers dispensed during the study period and by the
comparison of pre-test usage to post-test usage (figure 4.2).
There was no change in the perception of anesthesia providers regarding the use
of perioperative beta blockers before and after the PowerPoint intervention. There was
no change in awareness of a departmental beta blocker protocol noted in the post-test
compared to the pre-test despite the introduction of a written beta blocker order set and
risk assessment tool (figure 4.3) as part of the anesthesia preoperative orders. There was
no change in provider perception about the use of beta blockers in high and intermediaterisk patients noted in the post-test compared to the pre-test (figure 4.1).
There was no statistically significant change in the amount of beta blockers
dispensed perioperatively during the study period compared to the previous 90 days. The
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PowerPoint presentation seemed to have no effect in increasing the use of beta blockers
in the perioperative period.
Interventions
The study intervention consisted of a 25-slide PowerPoint presentation outlining
the rationale for beta blocker use in high and intermediate risk cardiac surgical patients
undergoing high and intermediate risk non-cardiac surgery. This presentation was
supplemented by a new pre-printed preoperative order set that included a risk assessment
tool and an easy check-box beta blocker order set. This order set was introduced at the
beginning of the study period and has become the default preoperative order set (preanesthesia orders before the study period and during the study period).
The implementation of the protocol was facilitated by the Chief of Anesthesia on
the day my project began. At the Department of Anesthesia bi-weekly meeting he passed
out the new pre-anesthesia order set that I created, which incorporates a risk assessment
tool along with easy to use checkboxes to facilitate beta blocker orders preoperatively.
The new and old order sets are in the Appendix. Because of the dynamics of the work
environment, it was felt that the introduction was best handled by him as a Departmental
initiative.
Lessons Learned
More than a 25-slide PowerPoint is needed to change anesthesia providers’
awareness of beta blocker usage in cardiac patients undergoing high and medium-risk
non-cardiac surgery. Facilitating this awareness with an easy-to-use preprinted order set
was not sufficient to change practice. Reinforcement by including a risk assessment tool
on the preprinted order set was also not sufficient to change provider practice.
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A more positive result may have been obtained with stronger buy-in from the
Department of Anesthesia leadership. Other strategies to improve increases in beta
blocker usage in appropriate patients could include a presentation at a Department
meeting followed by a group discussion about proper patient selection. Reinforcement
could also include a checkbox on the anesthesia record concerning beta blocker status.
Strengths and Weaknesses
The strength of this project is the application of evidence-based knowledge of
perioperative beta blocker usage in cardiac surgical patients undergoing non-cardiac
surgery to improve postoperative outcomes and decrease morbidity and mortality. The
major weakness of the project was the small number of participants (19), the short 90-day
duration of the study period, and the distinct possibility that the participants did not view
the 25-slide PowerPoint that outlined the evidence supporting perioperative beta blocker
usage in cardiac patients undergoing high and medium-risk non-cardiac surgery.
Clinical Practice Implications
Results indicate that heightened awareness of anesthesia providers did not occur
and did not lead to increased beta blocker use perioperatively. Controversy about patient
selection criteria for perioperative beta blockade remains. The evidence and the
ACC/AHA guidelines are clear for high-risk and low-risk patients. Even with riskassessment tools, it is not always clear which medium-risk patients will benefit from beta
blockers. The ACC/AHA guidelines for medium-risk patients are nonspecific and leave it
up to the individual provider to determine if the benefit of beta blocker administration
outweighs the risk of adverse outcomes such as hypotension, bradycardia and stroke.

31
Further clarification of the guidelines for medium-risk patients could promote increased
utilization of beta blockers in this patient population.
The participants in this study were all aware (100%) of the published literature on
the benefits of beta blocker therapy, but not all have incorporated this knowledge into
their practice. This may be due to individual reluctance to interpret national guidelines
and apply them clinically. It may also be due to their desire to not harm patients that may
not benefit from the administration of beta blockers.
Future Directions for Research
This investigator will seek to continue and expand this evidence-based project by
participating in the creation of a hospital-wide beta blocker order set as part of a new
computer physician order entry (CPOE). Another reinforcement strategy will be the
introduction of a patient’s beta blocker status into the verbal time-out that is routinely
performed right before any procedure starts. This confirmation of beta blocker status is
already a part of the verbal time out for all cardiac procedures and could be extended to
include all cardiac patients undergoing non-cardiac procedures.
More studies are needed to provide better evidence about the benefits of beta
blockers in high and intermediate risk cardiac patients undergoing high and intermediate
risk non-cardiac surgery. As evidence accumulates indicating better patient outcomes
when beta blockers are used appropriately, anesthesia providers may be more willing to
change their practice by incorporating this evidence. These studies should be large, multicenter prospective random controlled trials to validate the use of beta blockers in high
and intermediate-risk cardiac patients undergoing noncardiac surgery. It would be
especially important for these studies to focus on the kinds of beta blockers, doses,
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routes, and timing of administration that would optimize positive patient outcomes in this
particular patient population.
Conclusion
This evidence-based project has shown that no change in practice occurred after
dissemination of the best and most recent clinical evidence on perioperative beta blocker
administration to cardiac patients undergoing non-cardiac surgery. Other strategies will
need to be developed to increase anesthesia provider awareness, as well as to facilitate
beta blocker use in appropriate patients with the goals of improving clinical outcomes
and decreasing morbidity and mortality in this patient population.
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Appendix A: Consent to Participate

Dear Participant,
My name is Jody Heriot and I am a graduate student at the University of North
Florida. I am conducting research regarding the perioperative use of beta blockers. This
study will attempt to determine the perceptions of anesthesia providers regarding the use
of a perioperative beta blocker protocol before and after a PPT presentation designed to
provide information regarding the use of beta blockers in cardiac patients undergoing
non-cardiac surgery.
If you take part in my project, you will be asked to complete a survey, view a short PPT
presentation and complete a second survey. I will also be reviewing aggregate pharmacy
records to evaluate any changes in beta blocker usage during the study period. . This
project has been fully approved by the Institutional Review Boards of both the University
of North Florida and Holy Cross Hospital.
Participation in this study will take less than 30 minutes of your time over a 3 month
period. Your responses will be anonymous. No one other than Jody Heriot will see your
responses and your responses cannot be tied back to you. Although there are no direct
benefits to you or compensation for taking part in this study, others may benefit from the
information I find from the results of this study. Additionally, there are no foreseeable
risks for taking part in this project. Participation is voluntary with no penalties for not
responding to the questionnaire or ceasing participation. If you choose not to take part or
to withdraw from this study, there will be no penalty or loss of benefits to which you
would otherwise receive.
If you have any questions or concerns about this project, please contact me or my
professor. If you have questions about your rights as a participant, you may contact the
University of North Florida’s Institutional Review Board Chairperson, Dr. Katherine
Kasten, at 904-620-2498.
Thank you for your consideration.
Sincerely,
Jody Heriot, CRNA
Gerard Hogan, CRNA (Project Committee
Chair)
Phone: 954-849-5808
Phone (904) 252-0937
mothermuffet@aol.com
gerard.hogan@unf.edu
________________________________________ (print name) attest that I am at least
18 years of age and agree to take part in this study. A copy of this form was given to me.
Signature: ______________________________________ Date: __________________
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Appendix B: Beta Blockers and Surgical Outcomes Questionnaire

Please circle the most appropriate letter for each question.
1. Are you aware of studies in the literature related to prophylactic perioperative beta blocker use
in patients undergoing non-cardiac surgery who are at risk for cardiac complications?
a) YES
b) NO
2. In your opinion does prophylactic perioperative administration of beta blockers in patients with
known coronary artery disease, who are not already on regular beta blockers, have an effect on
postoperative outcomes?
a) STRONGLY AGREE
b) MILDLY AGREE
c) NEITHER AGREE NOR DISAGREE
d) MILDLY DISAGREE
e) STRONGLY DISAGREE
3. In your opinion does prophylactic perioperative administration of beta blockers in patients with
2 or more risk factors for coronary artery disease, who are not on regular beta blockers, have an
effect on postoperative outcomes?
a) STRONGLY AGREE
b) MILDLY AGREE
c) NEITHER AGREE NOR DISAGREE
d) MILDLY DISAGREE
e) STRONGLY DISAGREE
4. Does your department have a protocol for prophylactic perioperative beta blockade in patients
scheduled for non-cardiac surgery who are at risk for cardiac complications?
a) YES
b) NO
c) DON’T KNOW
5. How often do you use prophylactic beta blockers, as a routine part of perioperative care, in atrisk patients with known coronary artery disease or 2 or more risk factors for CAD?
a) ALWAYS
b) USUALLY
c) SOMETIMES
d) SELDOM
e) NEVER
6. Approximately how many times in an average week would you administer prophylactic beta
blockers?
a) 0
b) 1–2 TIMES
c) 3–5 TIMES
d) 5–10 TIMES
e) >10 TIMES
7. When do you generally start prophylactic beta blocker therapy?
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a) BEGIN SEVERAL DAYS AHEAD OF SURGERY IN OUTPATIENT CLINIC
b) MULTIPLE DOSES PREOP FOR INPATIENTS
c) SINGLE PREOP DOSE
d) POSTOPERATIVELY
8. How long do you generally continue prophylactic beta blocker therapy?
a) PREOPERATIVELY ONLY
b) EARLY POSTOPERATIVELY
c) DURATION OF HOSPITAL STAY
d) LONGER
9. In what type of surgery do you consider prescribing prophylactic beta blockers? (Choose any
that apply)
a) HIGH RISK (e.g. vascular, thoracic)
b) MODERATE RISK (e.g., major orthopedic, abdominal)
c) LOW RISK (e.g., cataract, peripheral)
10. Does type of anesthesia influence your decision to use prophylactic beta blockers (i.e.,
general, regional, local)?
a) YES
b) NO
11. When you use prophylactic beta blockers, what is your preferred drug?
a) METOPROLOL
b) ATENOLOL
c) ESMOLOL
d) OTHER
12. Do you use perioperative a2 agonists (e.g., clonidine) in patients with risk factors or known
cardio-vascular disease when beta blockers may be contraindicated?
a) ALWAYS
b) SOMETIMES
c) NEVER
13. Do you use a risk assessment tool to determine patient suitability for perioperative beta
blocker therapy?
a) ALWAYS
b) FREQUENTLY
c) OCCASIONALLY
d) NEVER
14. How long have you been practicing anesthesia?
a) 5 YEARS OR LESS
b) 5–10 YEARS
c) 10–15 YEARS
d) 15–20 YEARS
e)> 20 YEARS
15. What is your present age?
a) Under 30
b) 30–39
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c) 40–49
d) 50–59
e) >60
16. What is your gender?
a) MALE
b) FEMALE
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Appendix C: Post-intervention Order Set
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Appendix D: IRB Certificate
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Appendix D: Pre-intervention Order Set
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